THE PATHOBIOLOGY OF BILHARZIA-ASSOCIATED BLADDER CANCER

Nadia Mahmoud Mokhtar
Department of Pathology National Cancer Institute(NCI), Cairo University, Egypt

Nabil El Bolkainy
National Cancer Institute NCI, Cairo University Egypt

Hussein Khaled
National Cancer Institute NCI, Cairo University Egypt

Abdul Rahman Zekri
Department of Cancer Biology at the National Cancer Institute NCI, Cairo University Egypt

Keywords: Pathology, bladder cancer, classification, precancerous lesions, schistosomiasis, early detection and prevention, cancer genes, chromosomal analysis

Contents

1. Introduction
2. Precursor lesions
3. Classification
3.1 Transitional Cell Carcinoma
3.2 Papillary Transitional Neoplasm of Low Malignant Potential
3.3 Papillary Transitional Carcinoma
3.4 Invasive Transitional Carcinoma
3.5 Squamous Cell Carcinoma
3.6 Adenocarcinoma
3.7 Undifferentiated Tumors
3.8 Rare Variants
4. Early detection and chemoprevention
5. Biologic features
5.1 Chromosomal Changes
5.2 Cancer Genes
5.3 P53
5.4 Mdm2
5.5 Proliferation and cell cycle markers
5.6 Ras
5.7 Other Biologic Markers
5.8 Viruses
6. Conclusion
Glossary
Bibliography
Biographical sketches
Summary

Urinary bilharziasis is endemic throughout most of Africa, and the Middle East especially in Egypt. The highest incidence of bilharzia-associated bladder cancer (BABC) comes from Egypt. At the National Cancer Institute (NCI, Cairo), which is a specialized center in this disease the BABC presents with distinctive clinicopathologic features quite different from that reported from Europe and North America. However, time trend analysis showed a change in such pattern. WHO classification is used for its subtyping. The major differences in the clinicopathologic features observed between the Western type of bladder cancer and the BABC in Egypt may probably reflect underlying alternate tumor biology and carcinogenic pathways. From the pathogenic perspective, TCC occurring in Western industrial nations has been associated with cigarette smoking and exposure to aniline dyes, while bladder cancer in Egypt is associated with chronic bladder infection and schistosoma hematobium infestation. All such factors convey a direct carcinogenic insult to the urothelium, yet through variable mechanisms. BABC showed a special biologic pattern as revealed by different chromosomal alterations as well as genetic profile when compared to the Western pattern of bladder cancer. A proposed sequence of chromosomal aberrations in BABC is described. A high association between human papilloma virus (HPV) and BABC has been reported from Egypt with a possible viral-bilharzial association. HPV was higher in bilharzial cases than non-bilharzial ones. The study also revealed concordance between HPV and p53 of cases.

1. Introduction

Bilharziasis, also known as schistosomiasis, is a parasitic disease that dates back to antiquity. The ancient Egyptians, through settling and cultivating the Nile valley, were among the first to contract the disease. Thus, the main symptom hematuria was mentioned in Egyptian papyri (1500-1800 B.C.), and schistosome eggs were identified in Egyptian mummies through paleopathologic studies. In 1852, Theodor Bilharz, a German pathologist working in Cairo, discovered the worms in the portal circulation and was the first to describe the pathology of the disease. Ferguson in 1911 was the first to report on the high frequency of bladder cancer in Egypt and to suggest an etiologic relation with urinary bilharziasis, a fact which is now generally accepted.

Urinary bilharziasis is endemic throughout most of Africa, the Middle East, Madagascar, Reunion, Mauritius and India. In Africa, a high frequency is reported in countries along river Nile such as Egypt and Sudan, as well as, countries around lake Victoria as Kenya and Uganda. The disease is also prevalent in the west of the continent (Gold Coast and Senegal) and the eastern side of the continent below the Equator (Mozambique, Zambia and New Guinea). In the Middle East, it occurs in Iraq, Iran, Syria, Saudi Arabia and Yemen.

Schistosomiasis tends to reach its highest prevalence and severity where agriculture depends on irrigation such as in Egypt. In this situation, the irrigation and drainage canals provide a favorable environment for the snail intermediate host and a large number of people are infected repeatedly through contact with water all the year around. The geographic coincidence of bladder cancer and endemic bilharziasis is remarkable, with reported high frequency of bladder cancer in the above mentioned countries.
The highest incidence of bilharzia-associated bladder cancer (BABC) comes from Egypt (1). At the National Cancer Institute (NCI, Cairo), which is a specialized center in this disease, bladder cancer constituted 30.3% of all cancers, 40.6% of male cancers and 14.3% of female cancers. Conversely, in general hospitals, such as Cairo University Hospitals, a lower general frequency of 10.2% was reported. In a private pathology series, it was also the most common tumor encountered (20.6%), constituting 31.7% of male cancers and 5% of female cancers.

The BABC presents with distinctive clinicopathologic features quite different from that reported from Europe and North America (2). Thus, it affects patients at a much younger age (mean: 46.4 years) who present by cystitis rather than hematuria. The tumors are commonly nodular and usually arise from the upper vesical hemisphere. There is a high frequency (59%) of squamous cell carcinoma. Finally, the majority of tumors present at an advanced stage (95.3% of tumors > T1), hence radical cystectomy is the main line of treatment.

2. Precursor Lesions

The urothelium is a multipotential unstable epithelium, hence the multiple tumor types which may arise from it. A recently updated WHO classification (Table 1) is applicable to the BABC (6).

3. Classification

<table>
<thead>
<tr>
<th>Carcinoma in situ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transitional cell Carcinoma</td>
</tr>
<tr>
<td>Transitional neoplasm of low malignant potential</td>
</tr>
<tr>
<td>Papillary transitional carcinoma</td>
</tr>
<tr>
<td>Invasive transitional carcinoma</td>
</tr>
<tr>
<td>Transitional carcinoma variants</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>Conventional type</td>
</tr>
<tr>
<td>Verrucous type</td>
</tr>
<tr>
<td>Verrucoid type</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Mucinous type</td>
</tr>
<tr>
<td>Enteric type</td>
</tr>
<tr>
<td>Undifferentiated carcinoma</td>
</tr>
</tbody>
</table>

Table 1. The updated WHO histologic classification of bladder carcinoma

3.1 Transitional Cell Carcinoma
In the BABC, transitional cell carcinoma contributed about 25% of cases in large series collected over several years (2), but there has been an increase in its relative frequency in recent years (Table 2). Three histologic subtypes and 10 rare variants are recognized.

3.2 Papillary Transitional Neoplasm of Low Malignant Potential

This type is a papillary noninvasive tumor (Ta) which resembles a papilloma but with epithelial thickening exceeding the normal 6 layers. Histologically, it shows preserved normal cell polarity with intact umbrella cells and intact basement membrane, no cellular atypia, and infrequent mitosis restricted to basal cell layer. Rarely it may show a prominent endophytic or inverted pattern. Such tumors were previously classified as grade I transitional carcinoma in the 1973 WHO classification. However, long-term follow up studies have confirmed its rather benign nature. They frequently recur locally and rarely progress to muscle invasion, and hence are considered favorable tumors of borderline malignancy or very low malignant potential.

3.3 Papillary Transitional Carcinoma

This refers to papillary tumors, which are composed partially, or entirely of malignant transitional epithelium. This type may be invasive or noninvasive. It is usually exophytic in pattern, rarely endophytic. Histologically, it shows both architectural disorder, as well as, cellular atypia of variable degree. They are graded either on a scale of three (I, II, III) as recommended by WHO, or a scale of two (low and high grades), in such case the high grade includes WHO grade II and III.

3.4 Invasive Transitional Carcinoma

This describes a nonpapillary urothelial carcinoma that invades the bladder wall, hence an aggressive behavior is expected. Such invasive property may complicate a papillary tumor, or may arise de novo. Also, these tumors are graded either on a scale of 3, or a scale of 2 (low and high grades). For therapeutic and prognostic implications, it is important to describe the pattern of invasion at tumor margin, namely: expansile with broad-front or tentacular growth, as well as, the depth of invasion, namely: infiltration of lamina propria (focal or extensive) or muscularis propria. In BABC, The majority of tumors are invasive and 86% are high grade (2).

3.5 Squamous Cell Carcinoma

The high frequency of squamous cell carcinoma is one of the main distinctive features of carcinoma in the bilharzial bladder and has been noted for a long time in different reports from Egypt. A relative frequency of 59% was recently reported from the Urology and Nephrology Center of Mansoura. (2). This contrasts sharply with the relative infrequency of true squamous cell carcinoma in the Western world, which varied between 3% and 7% (7). The predominance of squamous cell carcinoma in bilharzial series is probably related to squamous metaplasia and dysplasia which are relatively common in chronic bilharzial cystitis that are frequently associated (65%) with this type of carcinoma (3). Histologically, squamous cell carcinoma is composed of one cell type exhibiting squamous differentiation throughout the tumor. Malignant squamous cells may exhibit one or more of the following
features according to their grade: eosinophilic cytoplasm, sharp cell borders, intercellular bridges, and concentric cellular formations of cell nests (squamous pearls). In bilharzial series, one half of cases are grade 1 or low grade with numerous cell nests and only slight nuclear anaplasia.

Verrucous carcinoma is an unusual variant of squamous carcinomas in the bilharzial bladder contributing 4.6% of squamous carcinoma or 3.4% of all types of bilharzial bladder carcinoma (8). Verrucous carcinomas are divided into pure form which is exceptionally rare, and verrucous carcinoma associated with an invasive component (verrucoïd carcinoma) which is more common. The former is a tumor of low malignant potential, but the latter will rather behave as conventional squamous cell carcinoma. Histologically, the tumor is a well differentiated, hyperkeratotic squamous cell carcinoma with elongated surface projections and down growths of club-shaped finger-like processes. The deeply advancing margin has a pushing rather than infiltrating border, where the cells are arranged in large bulbous masses of cohesive squamous cells.

The decline in the prevalence of bilharziasis in Egypt during the past two decades was associated with significant changes in the pathology of bladder carcinoma. This was confirmed by a time trend analysis study which demonstrated a significant decrease in bilharzia eggs in tissues, a decline in the relative frequency of squamous carcinoma and an increase of transitional carcinoma (Table 2).

3.6 Adenocarcinoma

Primary adenocarcinoma arises on top of cystitis glandularis, and is a rare tumor in western literature with a reported incidence of about 2%. This tumor type is more frequently encountered in areas where bilharziasis is endemic with a reported frequency variable between 6% (9) and 11% (2).

In a series of 185 patients of bilharzia-associated primary adenocarcinoma, (10) 32% were non-mucin producing enteric type, 54% with interstitial mucin production, 10% with intraluminal mucin and 4% with intracellular mucin or signet ring type.

TO ACCESS ALL THE 14 PAGES OF THIS CHAPTER, Visit: http://www.eolss.net/Eolss-sampleAllChapter.aspx

Bibliography


Ghoneim, M.A., EL-Mekresh. M.M., El-Baz, M.a., El-Attar, I.A. and Ashamallah, A. Radical cystectomy for
carcinoma of the bladder: critical evaluation of the results of 1,026 cases. J. Urol., (1997). 158:399. (This article studies the prognostic clinico-pathologic factors of bilhazial-associated bladder cancer in Egypt)

Khafagy, M.M., El-Bolkainy, M.N. and Monsour, M.A. Carcinoma of the bilharzial urinary bladder, a study of the associated mucosal lesion in 86 cases. Cancer (1972). 50:150-159. (This article studies the different mucosal changes in bilharzial bladder)


Gonzalez-Zulueta M, Shibata A, Ohnseit P.F. et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. JNCI, (1995) 87: 1383-1391. (This article is a pioneer work on chromosomal changes in Egyptian bladder cancer)


Khaled H, Aly M, Mokhtar N. Chromosomal aberrations in Cis and Ta bilharzial bladder cancer: A theory of
pathogenesis. In press. (This recent paper studies carcinoma-in situ and papillary tumors of bladder in terms of chromosomal changes)


Biographical Sketches

Dr. Nadia Mokhtar is Chairman of the Dept. of Pathology NCI, Cairo University since August 2001. She is a physician/ pathologist/ cytologist with more than thirty years experience in the field of surgical pathology, cytology, oncology, immunopathology and molecular pathology. As a professor of pathology at the National Cancer Institute of Cairo University, she had a long academic career and offered technical expertise to a
variety of national and international organizations and projects. She helped to establish a cancer pathology registry, immunopathology lab, molecular biology lab, electron microscopy lab at the Department of Pathology, NCI. She is a consultant pathologist/cytologist in several of cancer centers of the Ministry of Health, in several governorates in Egypt, including Damietta Cancer Center, Sohag Cancer Center, Fakouse Cancer Center and Mokatam Insurance Hospital. During her academic career she supervised more than 40 thesis in pathology, oncology and experimental studies. She published more than 60 papers in National and International Journals. She is a reference in malignant lymphoma and hematopoietic malignancies.

**Education:**

1978: Ph.D. Pathology, Barts Hospital, London University
1974: Diploma in Pathology/Bacteriology, Faculty of Medicine, Cairo University
1970: M.B.B.CH. Medical Degree, Faculty of Medicine, Cairo University

**Projects:**
Cytological screening for bilharzial cancer bladder in rural areas, malignant lymphoma: clinicopathologic profile, in collaboration with NCI, Bethesda, USA. Malignant complications of HCV, Co-principle Investigator, in collaboration with Georgetown University, USA. Mesothelioma, in collaboration with EORTC, molecular characterization of colorectal cancer in collaboration with MD Anderson. Malignant lymphoma by microarray, Co-investigator, in collaboration with King Faisal Specialist Hospital, Riyadh Saudi Arabia.

**International Organizations and posts:**
She is a member of the International Network for Cancer Treatment and Research (INCTR) Brussels, International Academy of Pathology, Arab Division of the International Academy of Pathology.
She is the associated editor of the Journal of the Egyptian National Cancer Institute since 2005.

**Teaching:**
Prof. Mokhtar teaches post graduate courses in pathology, cytology, immunopathology to medical oncologists and pathologists.

**Books:**
Cancer Pathology Registry: Published by NCI in 1991.
Molecular Pathology of Cancer: Published in 1998.
Lymphoma: Published in 2002.
Cancer Pathology Registry Published by NCI 2006

**Nabil El-Bolkainy** is a Professor of Pathology and ex-Daen of the National Cancer Institute.
**Husein Khaled** is a Professor of Medical Oncology and Dean of the National Cancer Institute
**Abdel Rahman Zekri** is a Professor of Virology, Department of Cancer Biology at the National Cancer Institute